BioCentury
ARTICLE | Clinical News

CVTX completes CARISA enrollment

April 10, 2001 7:00 AM UTC

CV Therapeutics completed enrollment of 648 chronic angina patients in an international Phase III trial of its ranolazine partial fatty acid oxidation (pFOX) inhibitor in combination with other angina...